Cancer Mutation Improves Chemo Drug Performance

River D'Almeida, Ph.D
2 min readAug 19, 2020

When it comes to cancer biomarkers, it’s often the genetic signatures that are associated with poor patient outcomes that take center stage. Take for example triple-negative breast cancer, a diagnostic marker for a condition that is notoriously difficult to treat and puts patients at significantly higher risks of relapse after therapy.

A team of cancer researchers based at the Terry Fox Research Institute have identified a gene mutation in lymphoma that serves as a biomarker for the opposite — it’s associated with improved patient survival instead.

Scientists David Scott and Christian Steidl led the study which was published in Nature Medicine. Here, they describe that patients with Diffuse Large B-cell Lymphoma, or DLBCL that lack a particular protein called TMEM30A are actually more susceptible to chemotherapeutic drugs, leading to better outcomes.

Shannon Healy, the first author of the paper said, “In contrast to most studies that describe gene mutations associated with poor survival, we observed that DLBCL cells with complete loss of TMEM30A actually showed increased uptake of cytotoxic drugs, most notably those that are used to treat DLBCL, such as doxorubicin and vincristine.”

DLBCL is the most common type of non-Hodgkin lymphoma worldwide. In the United States, almost 20,000…

--

--

River D'Almeida, Ph.D
River D'Almeida, Ph.D

Written by River D'Almeida, Ph.D

Follow me for bite-sized stories on the latest discoveries and innovations in biomedical research.